Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due…
Biopharmaceuticals
GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug
The growing scourge of food allergies drove U.K. heavyweight GSK to announce a $2.2 billion deal…
A small company can now advance its psychedelic into Phase 3. Here’s why that matters to other psychedelic biotechs.
Published: Jan. 5, 2026 at 9:01 a.m. ET A small biopharma company said its experimental depression drug…
Here’s why Pfizer is revising its revenue forecasts down
Last Updated: Dec. 16, 2025 at 9:26 a.m. ETFirst Published: Dec. 16, 2025 at 7:47 a.m. ET Pfizer…
Vaccine stocks slide as FDA official links COVID vaccines and heart conditions in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.
Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera
Management lowers full-year guidance, warns about competition, launches bid for Metsera.
These biotech stocks are getting hammered by shocking brittle-bone treatment study results
Published: Dec. 29, 2025 at 1:05 p.m. ET It’s looking like a poor end to 2025 for…